^Perl, Alexander E.; Altman, Jessica K.; Cortes, Jorge; Smith, Catherine; Litzow, Mark; Baer, Maria R.; Claxton, David; Erba, Harry P. et al. (2017). “Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, phase 1–2 study”. The Lancet Oncology18 (8): 1061–1075. doi:10.1016/S1470-2045(17)30416-3. PMC: 5572576. PMID 28645776. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572576/.
^Lee, Lauren Y.; Hernandez, Daniela; Rajkhowa, Trivikram; Smith, Samuel C.; Raman, Jayant Ranganathan; Nguyen, Bao; Small, Donald; Levis, Mark (2017). “Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor”. Blood129 (2): 257–260. doi:10.1182/blood-2016-10-745133. PMC: 5234222. PMID 27908881. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5234222/.
^“FDA Approval Sought for Gilteritinib in FLT3+ AML”. onclive.com. (2018年4月24日). https://www.onclive.com/web-exclusives/fda-approval-sought-for-gilteritinib-in-flt3-aml2018年9月29日閲覧。
…occurred less frequently with gilteritinib; the most common were grade ≥3 febrile neutropenia, anemia, and thrombocytopenia in 46, 41, and 23 percent, respectively. Gilteritinib is approved by the FDA for …
…AML with FLT3 mutations, gilteritinib, an orally available inhibitor of mutated FLT3, improved survival and remission rates compared with salvage chemotherapy . The gilteritinib group experienced fewer …
…AML with FLT3 mutations, gilteritinib, an orally available inhibitor of mutated FLT3, improved survival and remission rates compared with salvage chemotherapy . The gilteritinib group experienced fewer …
…of remission induction therapy. Ivosidenib, enasidenib, and gilteritinib – For patients receiving ivosidenib, enasidenib, or gilteritinib for AML, withdrawal of these agents is unlikely to be effective …
…patients who experience signs or symptoms of ILD or pneumonitis without an infectious cause. Gilteritinib – Gilteritinib is a second orally active inhibitor of FLT3 and is approved for use in patients with AML …